Moleculin Biotech, Inc. (MBRX) — Analyst outlook / Analyst consensus target is. Based on 4 analyst ratings, the consensus is bullish — 4 Buy.
Analysts estimate Earnings Per Share (EPS) of $-190.08 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-6.32 vs est $-190.08 (beat +96.7%). 2025: actual $-28.42 vs est $-36.35 (beat +21.8%). Analyst accuracy: 0%.
MBRX Analyst Ratings
Buy
Based on 4 analysts giving stock ratings to Moleculin Biotech, Inc. in the past 3 months
EPS Estimates — MBRX
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$6.32
vs Est –$190.08
▲ 2,907.6% off
2025
Actual –$28.42
vs Est –$36.35
▲ 27.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — MBRX
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
